ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the…
ImmunoGen Inc. announced that the US Food and Drug Administration (FDA) has granted accelerated approval for ELAHERE (mirvetuximab soravtansine-gynx) for the treatment of adult patients…
Read More...
Read More...